In this episode of the Vital Health podcast, host Duane Schulthess sits down with Steve Potts, a seasoned entrepreneur and CEO of SLAM BioTherapeutics. They dive deep into the challenges and opportunities in biotech, exploring how recent legislative changes, like the IRA, are reshaping the industry. Steve shares insights on the shift from small molecules to biologics, the funding landscape, and the critical role of American innovation in drug development. Tune in to hear about the state of biotech in the U.S., the future of drug discovery, and what it takes to succeed in this evolving field.Continue reading→

The 2024 AZBio Trailblazer Honorees are: Senator Eva Burch, FNP-C; Senator Brian Fernandez; Senator David Gowan; Senator John Kavanaugh; Senator Janae Shamp, BSN, RN; Senator T.J. Shope; Representative Selina Bliss; Representative David Livingston; Representative Stacy Travers; and Representative Julie Willoughby, TCRN. Continue reading→

At the ASU Venture Devils program, on Saturday, November 16th 2024, 70-90 top student ventures will be pitching for varying amounts of seed funding from various funding tracks associated with the Venture Devils program. This large-scale event is happening in-person at ASU SkySong in Scottsdale, AZ. Volunteer VIP Judges are needed to provide thoughtful and thorough evaluations of these teams. We are looking for diverse, interdisciplinary judging panels and for consistency with this across all judging rooms. These panels will be assembled based on the sign-up response in coordination with the judges and stakeholders that are participating. We will notify you if you’ve been selected as a judge at least one week prior to the event. Continue reading→

The Arizona Biomedical Research Centre (ABRC) invites you to conduct peer reviews of research grant applications on behalf of the Arizona Department of Health Services. The ABRC relies on subject matter experts (SMEs) from around the globe to evaluate the merits of the grant applications, and solicits their participation as needed. Continue reading→

• License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries –
• Gilead Plans to PriceProduct at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand –
• Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV –

Continue reading→

A serious, irreversible eye disease known as myopic maculopathy is on the rise. Yalin Wang, a professor of computer science and engineering in the School of Computing and Augmented Intelligence at ASU, is leading a team to find solutions. Continue reading→

First subject vaccinated with investigational vaccine for early-stage hemangiosarcoma in combination with standard treatment

Hemangiosarcoma, or HSA, is a common and uniformly fatal cancer in dogs, with particularly high incidence in some popular breeds.Continue reading→

TUCSON, Ariz., September 30, 2024 — Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.Continue reading→

The submission deadline is October 17, 2024. 

Download the 2025 Submission Guide.

Individuals whose proposals have been selected will be notified mid-January 2025.Continue reading→